NKGen Biotech (NKGNW) Stock Price, News & Analysis

Company Overview

NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based immunotherapies for cancer and neurodegenerative diseases. The company’s technology is designed to enhance the ability of NK cells to identify and destroy abnormal cells while supporting their activity in the body.

NKGen’s lead product candidate is SNK01, an autologous NK cell therapy produced from a patient’s own cells. The company has evaluated SNK01 in clinical studies involving cancer and is also investigating its potential in neurodegenerative conditions, including Alzheimer’s disease. NKGen is developing additional candidates and applications based on its proprietary “supercharged” NK cell platform, including approaches involving allogeneic, or donor-derived, cells.

The company’s operations and development activities have involved the United States and South Korea. NKGen Biotech became a publicly traded company through a business combination with Graf Acquisition Corp. IV in 2023. Its leadership has included physician and biotechnology executive Paul Song, M.D., who has served as chief executive officer and has been involved in advancing the company’s NK cell technology and clinical development programs.

Key Stats

• Today's Range: $0.0003 to $0.0003
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.15
• Volume: N/A
• Average Volume: 276,500 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NKGNW
• CIK: 1845459
• Web: nkgenbiotech.com
• Phone: 949-396-6830
• Fax: N/A
• Employees: 63
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A